Structure of a key “trigger” of the immune response solved
Posted: 27 August 2024 An international collaboration, involving researchers from Monash University and the University of Oxford, has led to a breakthrough in our understanding of how immune responses are started. The study has just been published in Nature. The human…
Florey quantum technology project FeBI on track to transform blood tests for iron disorders
Posted: 27 August 2024 Quantum sensors that will revolutionise diagnosis and management of iron disorders, move to its next phase, thanks to AEA funding. An estimated 1 in 5 women (and 1 in 20 men) in Australia are…
Five Patients Recording a Sustained Reduction in Tumor Size in ACCENT Trial
Posted: 22 August 2024 Amplia Therapeutics Limited is pleased to announce that a fifth patient enrolled in the Company’s Phase 2a clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30% or greater decrease…
Noxopharm Targets Clinical Trial for First-in-Class Drug
Posted: 22 August 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce its first in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial is planned to start in early calendar year 2025…
Optiscan Signs MOU with University of Minnesota College of Veterinary Medicine
Posted: 22 August 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘the Company’) is pleased to announce that it has signed a Memorandum of Understanding (MOU) with the prestigious University of Minnesota College of Veterinary Medicine. Under the terms…
INOVIQ Exosome Platform Validated for Parkinson’s Disease EV Isolation
Posted: 22 August 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has further validated its NEURONET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). On June 24th this year, INOVIQ reported that…
Noxopharm Targets Clinical Trial for First-in-Class Drug
Posted: 19 August 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce its first in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial is planned to start in early calendar year 2025…
Global launch of geneType™ on wholly owned EasyDNA platform
Posted: 19 August 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch…
ANDHealth & TGA extend partnership
Posted: 19 August 2024 A joint initiative between ANDHealth and the Therapeutic Goods Administration (TGA) will continue providing regulation and registration support for digital medical software companies looking to commercialise new products that can help improve health outcomes…
